226 Users Online
Chymotrypsin Test Market Segmented By Indication such as Pancreatic Disorders, Cancer and Malnutrition
Chymotrypsin test is done to check the pancreatic functioning, this test help to identify the Pancreatic Insufficiency towards the production of digestive enzymes. Chymotrypsin is an enzyme which is responsible for the digestion of proteins in a small intestine. Chymotrypsin test measures the amount of chymotrypsin in the stool that helps to identify the pancreas functioning.
Chymotrypsin test is normally used along with another test such as fecal fat test, urine test, etc. Chymotrypsin test is done to diagnose acute or chronic pancreatic disorders. It is frequently associated with pancreatic disorders. In children, chymotrypsin test is done to diagnose the cystic fibrosis (CF) or Shwachman-Diamond Syndrome (SDS).
Chymotrypsin test is done on the stool sample within a 72 hour period for getting the proper results. Chymotrypsin test is based on the ELISA test principle, which identifies the chymotrypsin enzyme in the stool. In chymotrypsin test market, kits are available in 48-Strip-Wells, 96-Strip-Wells.
Rising patient pool suffering from the acute and chronic pancreatic disorders may drive the chymotrypsin test market. People suffering from the disorders like indigestion, gastroesophageal reflux disease (GERD) may show the fueling growth for chymotrypsin test market.
Disease conditions like persistent diarrhea, vitamin deficiency, malnutrition will show the additional demand of the chymotrypsin test market. In children cystic fibrosis (CF) or Shwachman-Diamond Syndrome (SDS) diagnosis may show the propelling growth for chymotrypsin test market.
Alternative diagnosis methods like CT scan, Endoscopy for the pancreatic testing may show the slower growth for chymotrypsin test market. Awareness of the people about the cystic fibrosis and pancreatic cancer may show the stagnancy in the chymotrypsin test market.
|Based on indication||
|Based on end user||
Rising population of the pancreatic disorders is the main factor for the growth of chymotrypsin test market, however by indication type, pancreatic disorders expected to show the good revenue for the chymotrypsin test market. Cancer segment covers the various cancer related to the GIT, such as intestine cancer, stomach cancer etc., rising patient pool of GIT related complications and cancers expected to fuel the growth of the chymotrypsin test market.
In the developing countries like India, South Africa & Brazil children suffering from the malnutrition related problems, in such scenarios malnutrition diagnosis will show the good revenue for the chymotrypsin test market. By end user, hospitals segment expected to the high revenue share for the chymotrypsin test market, since the majority of population visiting to the hospitals is high, for the diagnosis of various disorders.
Followed by the hospitals clinics wills show the good revenue for the chymotrypsin test market, since people normally visits the specialty clinics for the GIT related complications. Diagnostic center segment will show the lucrative growth in a developed countries for chymotrypsin test market, due to the more number of diagnostic and pathology labs in the developed countries, and people also visits for the routine body check up in the diagnostic center.
Among the regional presence, North America will show the high revenue for the chymotrypsin test market, since the people are more concern about the GIT track related complications. After North America, the Europe region will show the propelling growth for a chymotrypsin test market in the near future, since the good hospital infrastructure and more number of hospitals in the Europe region.
Latin America region will show the good demand for the chymotrypsin test market, due to the regional government imitative towards the public health care program, Brazil market will be the most lucrative market for chymotrypsin test.
In Asian countries like China and India, the rate of the colon and rectum cancer is high due to the lifestyle pattern and unhygienic conditions, this condition may show the additional demand for the chymotrypsin test market. The Middle East and Africa are expected to account for being the least lucrative market for chymotrypsin test due to lack of awareness about the chymotrypsin test-related disorders in people.
Some of the key players across the value chain of chymotrypsin test market are Fisher Scientific UK Ltd., BioVision Inc., Biocompare, Promega Corporation, ALPCO, elabscience, Eurofins DiscoverX Corporation, Immunodiagnostic Systems, Worthington Biochemical Corporation, Creative Proteomics, Bio-Rad Laboratories, Inc.and others.